UNSPSC 51142523: Diprobutine

This classification denotes an antiparkinsonian agent with the molecular formula C10H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5XE7IWD0JX, chemically known as 1,1-dipropylbutylamine but generally known as diprobutine, which bears US NIH Compound Identifier 41701. European Medicines Agency schedules Diprobutine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07221MIG.

UNSPSC 51142523 Diprobutine is a Commodity code, though the recent state and local solicitations tagged with it show limited direct relevance to the code's narrow chemical name. The opportunities instead reflect broader pharmaceutical and drug-related procurement across health agencies: Seminole County, Florida is seeking Naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited generic multi-source pharmaceuticals and OTC products through an RFP. The scope of work under recent tags spans emergency response medications, pharmacy benefit program infrastructure, and generic pharmaceutical supply chains serving state and local health systems, rather than diprobutine specifically. Issuing bodies include county health departments, state health agencies, and cooperative purchasing organizations representing multiple jurisdictions.

Geographic activity centers on Texas, Minnesota (with participating states including Oregon), and Florida, based on recent solicitations. The Seminole County IFB for Naloxone and drug deactivation systems (IFB60459723LAS, due Jul 26, 2023) calls for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries; bidders must submit electronically through the county's e-Procurement Portal and include all shipping and delivery costs, with a two-year initial contract term and one-year renewal option. The Texas HHS Commission's RFI (HHS0017013, posted Apr 3, 2026) sought vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional PBM and GPO channels. The MMCAP RFP (S1070000015802, due Mar 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026, and evaluation weighted heavily on price competitiveness (75 percent), cGMP and DSCSA compliance, and EDI capability.